Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
MD Snape, T Dawson, P Oster, A Evans… - The Pediatric …, 2010 - journals.lww.com
MD Snape, T Dawson, P Oster, A Evans, TM John, B Ohene-Kena, J Findlow, LM Yu…
The Pediatric infectious disease journal, 2010•journals.lww.comBackground: An investigational vaccine against serogroup B meningococcal (MenB)
disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial
adhesion A, and Neisserial heparin-binding antigen) has been developed. We evaluated
the immunogenicity and reactogenicity of a 3-dose course of this vaccine administered
alone (recombinant MenB [rMenB]) or combined with the outer membrane vesicle (OMV)
component of the vaccine used in New Zealand (rMenB+ OMV). Methods: A randomized …
disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial
adhesion A, and Neisserial heparin-binding antigen) has been developed. We evaluated
the immunogenicity and reactogenicity of a 3-dose course of this vaccine administered
alone (recombinant MenB [rMenB]) or combined with the outer membrane vesicle (OMV)
component of the vaccine used in New Zealand (rMenB+ OMV). Methods: A randomized …
Abstract
Background:
An investigational vaccine against serogroup B meningococcal (MenB) disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, and Neisserial heparin-binding antigen) has been developed. We evaluated the immunogenicity and reactogenicity of a 3-dose course of this vaccine administered alone (recombinant MenB [rMenB]) or combined with the outer membrane vesicle (OMV) component of the vaccine used in New Zealand (rMenB+ OMV).
Methods:
A randomized, single-blind, comparative study of 60 healthy infants enrolled at 6 to 8 months of age and immunized with rMenB or rMenB+ OMV at day 0, day 60, and at age 12 months. Blood samples obtained at baseline and 1 month following the second and third doses of vaccine were analyzed for serum bactericidal antibody (SBA) using human complement (hSBA) against 7 MenB strains. The putative correlate of protection was an hSBA titer of≥ 4.
Results:
The per-protocol analysis included 24 of 30 participants randomized to each group. After 3 doses of rMenB+ OMV, 90% or more of participants had an hSBA titer≥ 4 for 5 MenB strains, with 70% of participants having an hSBA titer≥ 4 for a sixth strain. rMenB alone was immunogenic for only 3 strains. Both vaccines were well tolerated.
Conclusions:
Three doses of rMenB+ OMV in the second half of infancy induce bactericidal antibodies against strains expressing vaccine antigens, demonstrating the potential for broader vaccine prevention of MenB disease. This vaccine is now in phase III clinical trials.
Lippincott Williams & Wilkins